- Home
- OCUL vs PGEN Comparison
OCUL vs PGEN Comparison
Compare OCUL & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | PGEN |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OCUL | PGEN |
|---|---|---|
| Price | $10.76 | $3.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $22.90 | $7.67 |
| AVG Volume (30 Days) | ★ 7.6M | 4.3M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,990,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $9.35 | $342.78 |
| Revenue Next Year | $92.88 | $478.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.48 | N/A |
| 52 Week Low | $6.23 | $1.11 |
| 52 Week High | $16.44 | $5.47 |
Technical Indicators
Market Signals| Indicator | OCUL | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 31.99 |
| Support Level | $10.65 | $2.99 |
| Resistance Level | $12.63 | $5.10 |
| Average True Range (ATR) | 0.75 | 0.36 |
| MACD | 0.40 | -0.14 |
| Stochastic Oscillator | 85.67 | 4.06 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.